They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The decision is based on the phase 3 DESTINY-Breast11 trial
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Subscribe To Our Newsletter & Stay Updated
